Skip to main content
Caplight Logo









Ansun BioPharma

Ansun BioPharma

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://www.ansunbiopharma.com/

Last Round

Series B

Oct 14, 2019

Total Funding Raised

$215M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Ansun BioPharma is a biopharmaceutical company that develops host-directed recombinant protein therapeutics to treat severe viral respiratory infections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalantiviraldrug discoveryclinical trialsrespiratory virusbiotechhost-directed therapyinfectious diseaseDAS181clinical-stage biotechNational Institutes of HealthNIHdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ansun BioPharma Comparables

Compare Ansun BioPharma with similar companies based on industry and business-model similarity.

Ansun BioPharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Altesa BioSciences
78%
Synairgen plc
77%
Cocrystal Pharma Inc
73%

Ansun BioPharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 14, 2019
Series AMay 14, 2018
GrantSep 1, 2006

Key People

Founding team and executive leadership

Nancy Chang

Chief Executive Officer

Executive Team

Ansun BioPharma Investors

Notable investors and investment history

Ansun BioPharma investors
InvestorRounds
MatrixSeries B, Series A
Korea Investment PartnersSeries B
Bencao CapitalSeries B, Series A
NIH RADxGrant
Next CapitalSeries B
Junson CapitalSeries B
LYFE CapitalSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 28, 2026

    Monthly visitors increased 89% MoM.

  • May 14, 2018

    $85M round led by Lilly Asia Ventures

Ansun BioPharma Filings

Explore SEC and related filing metadata, where available.

Ansun BioPharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Ansun BioPharma's valuation, stock price, and market status.

Is Ansun BioPharma a public or private company?

Ansun BioPharma is a private company.

What is the current stock price of Ansun BioPharma?

Ansun BioPharma is a private company with no public stock price. No recent secondary market data is available.

How much is Ansun BioPharma worth (valuation)?

Valuation information for Ansun BioPharma is not publicly available.

Can I buy Ansun BioPharma stock?

Ansun BioPharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Ansun BioPharma's last funding round?

Ansun BioPharma's most recent funding round was Series B on October 1, 2019.

Who are the main investors in Ansun BioPharma?

Key investors in Ansun BioPharma include Oceanpine Capital, Lilly Asia Ventures.

Will Ansun BioPharma IPO soon?

No public IPO plans have been announced for Ansun BioPharma.

How can I track Ansun BioPharma secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ansun BioPharma's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Diego, California
Employee Range11
Year Founded2003
Last FundingOct 14, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?